Endocrinology · Radiology · Geriatrics

2010 CAROC Fracture Risk calculator

Enter the published formula inputs below to calculate and interpret this score.

Clinical inputs

Sex

Age

years

Allowed range: 50–110 years

The closest printed row among 50, 55, 60, 65, 70, 75, 80, and 85 is used. An age exactly halfway between two rows is not scored. Under 50 years is not scored.

Femoral-neck T-score

T-score

Allowed range: -6–3 T-score

NHANES III white-woman reference. Low is above the first printed T-score for that row. Moderate runs from that value through the second printed T-score. High is below the second.

Spine or total-hip T-score of −2.5 or lower

Fragility fracture after age 40

Craniofacial, hand, ankle, and foot fractures are excluded. One non-hip, non-vertebral fracture raises the zone by one category. A hip or vertebral fracture, or more than one fragility fracture, is high risk.

Glucocorticoid use

Result

4 fields remaining

Anyone can run this calculator. Sign in to save, favourite, or send the result.

Primary source

Lentle B et al. Osteoporosis Canada 2010 guidelines for the assessment of fracture risk. Can Assoc Radiol J. DOI: 10.1016/j.carj.2011.05.001. PMID: 21852066. Table 4 gives femoral-neck T-score zones for women and men at ages 50, 55, 60, 65, 70, 75, 80, and 85. Low risk is above the first printed T-score, moderate risk is that T-score through the second printed T-score, and high risk is below the second. Use the row closest to the patient's age. The femoral-neck T-score uses the NHANES III white-woman reference. A spine, total-hip, or femoral-neck T-score of −2.5 or lower, the Table 1 definition of osteoporosis, is at least moderate risk. A fragility fracture after age 40 or recent glucocorticoid use (at least 3 months in the past year at a prednisone-equivalent dose of 7.5 mg daily or higher) raises the zone by one category. Both of those factors, a hip or vertebral fragility fracture, or more than one fragility fracture is high risk regardless of BMD. Fragility fractures exclude craniofacial, hand, ankle, and foot fractures. Low is under 10% major osteoporotic fracture risk in 10 years, moderate is 10% to 20%, and high is over 20%. (2011)

Scope: Women and men 50 years or older. The result is the risk category for a person who has not been treated. An age exactly halfway between two printed rows is not scored, because the paper does not give a tie rule.

Last reviewed 2026-10-17

View source

Professional use only

For qualified clinicians. Independently verify inputs, calculations, source guidance, and applicability before any clinical action. This calculator does not replace clinical judgment.

Source: Lentle B et al. Osteoporosis Canada 2010 guidelines for the assessment of fracture risk. Can Assoc Radiol J. DOI: 10.1016/j.carj.2011.05.001. PMID: 21852066. Table 4 gives femoral-neck T-score zones for women and men at ages 50, 55, 60, 65, 70, 75, 80, and 85. Low risk is above the first printed T-score, moderate risk is that T-score through the second printed T-score, and high risk is below the second. Use the row closest to the patient's age. The femoral-neck T-score uses the NHANES III white-woman reference. A spine, total-hip, or femoral-neck T-score of −2.5 or lower, the Table 1 definition of osteoporosis, is at least moderate risk. A fragility fracture after age 40 or recent glucocorticoid use (at least 3 months in the past year at a prednisone-equivalent dose of 7.5 mg daily or higher) raises the zone by one category. Both of those factors, a hip or vertebral fragility fracture, or more than one fragility fracture is high risk regardless of BMD. Fragility fractures exclude craniofacial, hand, ankle, and foot fractures. Low is under 10% major osteoporotic fracture risk in 10 years, moderate is 10% to 20%, and high is over 20%. (2011)

Ruqelo is AI and can make mistakes. Check important information.

Clinical inputs

Sex
Age (years)Accepted range: 50 to 110
Femoral-neck T-scoreAccepted range: -6 to 3
Spine or total-hip T-score of −2.5 or lower
Fragility fracture after age 40
Glucocorticoid use

Primary source

View source